Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
MC2 Therapeutics
MC2 Therapeutics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Wynzora
Betamethasone
,
Calcipotriene
2020-07-20
2027-2039
Psoriasis
,
Atopic dermatitis
,
Pruritus ani
,
Inflammation
,
Facial dermatoses
,
Seborrheic dermatitis
,
Foot dermatoses
,
Hand dermatoses
,
Scalp dermatoses
,
Leg dermatoses
,
Mycoses
,
Oral candidiasis
,
Vulvovaginal candidiasis
,
Tinea pedis
,
Cutaneous candidiasis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Betamethasone
psoriasis
Calcipotriene
psoriasis
Betamethasone dipropionate
vasoconstriction
,
photoallergic dermatitis
,
phototoxic dermatitis
,
psoriasis
Bos taurus adrenal cortex corticosteroids
multiple myeloma
,
psychology rejection
,
melanoma
,
plasma cell neoplasms
,
heart transplantation
,
graft rejection
,
renal cell carcinoma
,
lung neoplasms
,
immunoglobulin g4-related disease
,
covid-19
,
lupus nephritis
,
nephritis
,
systemic lupus erythematosus
,
respiratory tract diseases
,
vascular diseases
,
lung diseases
,
vasculitis
,
granulomatosis with polyangiitis
,
anti-neutrophil cytoplasmic antibody-associated vasculitis
,
systemic vasculitis
,
kidney transplantation
,
epstein-barr virus infections
Daivonex
psoriasis
,
coronary artery disease
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use